RBC Capital Reinstates Outperform on Alexion Pharmaceuticals, Announces $135 Price Target

 

RBC Capital Reinstates Outperform on Alexion Pharmaceuticals, Announces $135 Price Target

Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, …

More RBC Capital Reinstates Outperform on Alexion Pharmaceuticals, Announces $135 Price Target Videos

Leave a Reply